Similar articles

• The safety and efficacy of bortezomib in relapsed multiple myeloma.

  Jagannath S. Jagannath S. Clin Adv Hematol Oncol. 2006 May;4(5):2-3; discussion 8; suppl 13. Clin Adv Hematol Oncol. 2006. PMID: 16830423 No abstract available.
• Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.

  Richardson P, Jagannath S, Colson K. Richardson P, et al. Clin Adv Hematol Oncol. 2006 May;4(5):1; discussion 8; suppl 13. Clin Adv Hematol Oncol. 2006. PMID: 16830422
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

  Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Richardson PG, et al. J Clin Oncol. 2006 Jul 1;24(19):3113-20. doi: 10.1200/JCO.2005.04.7779. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754936 Clinical Trial.
• Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

  Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. Badros A, et al. Cancer. 2007 Sep 1;110(5):1042-9. doi: 10.1002/cncr.22921. Cancer. 2007. PMID: 17654660 Review.
• A practical update on the use of bortezomib in the management of multiple myeloma.

  San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. San Miguel J, et al. Oncologist. 2006 Jan;11(1):51-61. doi: 10.1634/theoncologist.11-1-51. Oncologist. 2006. PMID: 16401713 Review.